Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Boehringer Ingelheim
Colorcon
Baxter

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR ESKALITH


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Eskalith

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed National Institute of Mental Health (NIMH) Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed Washington University School of Medicine Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00221975 ↗ Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling Completed University Hospitals Cleveland Medical Center Phase 3 2002-07-01 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a combination of lithium and divalproex. Once these medications are tolerated, they are randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in this study until they experience a marked bimodal response for four consecutive weeks. This study is sponsored by the Stanley Foundation.
NCT00408681 ↗ Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed National Cancer Institute (NCI) N/A 2006-06-01 RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
NCT00408681 ↗ Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed Fred Hutchinson Cancer Research Center N/A 2006-06-01 RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
NCT00601575 ↗ Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions Completed Roxane Laboratories N/A 2002-10-01 The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fed conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eskalith

Condition Name

Condition Name for Eskalith
Intervention Trials
Bipolar Disorder 7
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) 2
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) 2
Recurrent Adult Acute Myeloid Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eskalith
Intervention Trials
Bipolar Disorder 8
Depression 2
Leukemia, Myeloid, Acute 2
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eskalith

Trials by Country

Trials by Country for Eskalith
Location Trials
United States 25
Sweden 2
Canada 2
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eskalith
Location Trials
Ohio 4
Pennsylvania 3
California 2
Michigan 2
Arkansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eskalith

Clinical Trial Phase

Clinical Trial Phase for Eskalith
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 1 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eskalith
Clinical Trial Phase Trials
Completed 10
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eskalith

Sponsor Name

Sponsor Name for Eskalith
Sponsor Trials
National Institute of Mental Health (NIMH) 4
Washington University School of Medicine 2
University Hospitals Cleveland Medical Center 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eskalith
Sponsor Trials
Other 12
NIH 6
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
McKinsey
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.